Cargando…

Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer

Hypoxia, low oxygen (O(2)) level, is a hallmark of solid cancers, especially hepatocellular carcinoma (HCC), one of the most common and fatal cancers worldwide. Hypoxia contributes to drug resistance in cancer through various molecular mechanisms. In this review, we particularly focus on the roles o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Macus Hao-Ran, Wong, Carmen Chak-Lui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304710/ https://www.ncbi.nlm.nih.gov/pubmed/34359884 http://dx.doi.org/10.3390/cells10071715

Ejemplares similares

Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer
por: Zhang, Misty Shuo, et al.
Publicado: (2022)

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
por: Cheu, Jacinth Wing-Sum, et al.
Publicado: (2023)

Genome‐Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment
por: Yang, Chunxue, et al.
Publicado: (2022)

Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
por: Lei, Pan, et al.
Publicado: (2023)

Metabolic Reprogramming of Liver Fibrosis
por: Delgado, M. Eugenia, et al.
Publicado: (2021)

Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer
por: Fan, Chaofan, et al.
Publicado: (2021)

Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming
por: Zwaans, Bernadette M. M., et al.
Publicado: (2014)

Hypoxia- and MicroRNA-Induced Metabolic Reprogramming of Tumor-Initiating Cells
por: Ullmann, Pit, et al.
Publicado: (2019)

Targeting Hypoxia-Driven Metabolic Reprogramming to Constrain Tumor Progression and Metastasis
por: Miranda-Galvis, Marisol, et al.
Publicado: (2020)

Ferroptosis Suppressor Protein 1 Inhibition Promotes Tumor Ferroptosis and Anti-tumor Immune Responses in Liver Cancer
por: Cheu, Jacinth Wing-Sum, et al.
Publicado: (2023)

Relationship between metabolic reprogramming and drug resistance in breast cancer
por: Lv, Linlin, et al.
Publicado: (2022)

Novel drugs that target the metabolic reprogramming in renal cell cancer
por: van der Mijn, Johannes C., et al.
Publicado: (2016)

Potential role of the N-MYC downstream-regulated gene family in reprogramming cancer metabolism under hypoxia
por: Lee, Ga Young, et al.
Publicado: (2016)

Hypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation
por: Aird, R., et al.
Publicado: (2022)

Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma
por: Nguyen, Trang T. T., et al.
Publicado: (2022)

Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance
por: Hirpara, Jayshree, et al.
Publicado: (2018)

DEHP mediates drug resistance by metabolic reprogramming in colorectal cancer cells
por: Wu, Yue, et al.
Publicado: (2023)

Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy
por: Huang, Mingyao, et al.
Publicado: (2020)

Metabolic reprogramming in cancer: mechanistic insights from Drosophila
por: Lam Wong, Kenneth Kin, et al.
Publicado: (2021)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Single-cell characterization revealed hypoxia-induced metabolic reprogramming of gastric cancer
por: Kou, Wenjia, et al.
Publicado: (2022)

Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis
por: Wong, Carmen Chak-Lui, et al.
Publicado: (2014)

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer
por: Chetta, Paolo, et al.
Publicado: (2021)

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
por: Chen, Helen H. W., et al.
Publicado: (2010)

Metabolic Reprogramming in the Opportunistic Yeast Candida albicans in Response to Hypoxia
por: Burgain, Anaïs, et al.
Publicado: (2020)

Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
por: Li, Zhenzhen, et al.
Publicado: (2021)

Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma
por: Gu, Young-Ran, et al.
Publicado: (2022)

Metabolic reprogramming in prostate cancer
por: Ahmad, Fahim, et al.
Publicado: (2021)

The roles of glucose metabolic reprogramming in chemo- and radio-resistance
por: Lin, Jinguan, et al.
Publicado: (2019)

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance: Metabolic reprogramming of the OC microenvironment
por: Yue, Huiran, et al.
Publicado: (2023)

Metabolic Reprogramming in Mitochondria of Myeloid Cells
por: Zuo, Hao, et al.
Publicado: (2019)

The cancer metabolic reprogramming and immune response
por: Xia, Longzheng, et al.
Publicado: (2021)

Lipid metabolic reprogramming in cancer cells
por: Beloribi-Djefaflia, S, et al.
Publicado: (2016)

Evolutionary Origins of Metabolic Reprogramming in Cancer
por: García-Sancha, Natalia, et al.
Publicado: (2022)

The Role of Reprogrammed Glucose Metabolism in Cancer
por: Ediriweera, Meran Keshawa, et al.
Publicado: (2023)

Metabolic reprogramming in cancer: Mechanisms and therapeutics
por: Nong, Shiqi, et al.
Publicado: (2023)

Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer
por: Feng, William W., et al.
Publicado: (2020)

Cysteine Boosts Fitness Under Hypoxia-Mimicked Conditions in Ovarian Cancer by Metabolic Reprogramming
por: Nunes, Sofia C., et al.
Publicado: (2021)

Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
por: Wu, Si-Han, et al.
Publicado: (2014)

Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming
por: Han, Rongrong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmhtv7pc1ptqhktuklljbqhepp